Analisis Risiko Penyakit Jantung Koroner Pada Populasi Dewasa Menggunakan Kombinasi Score Framingham dan Kadar Asam Urat

Leddy N Rumansara; Nuraliah Rusman

doi:10.55338/jumin.v7i3.8408

Authors

Leddy N Rumansara Universitas Cenderawasih
Nuraliah Rusman Universitas Cenderawasih

DOI:

https://doi.org/10.55338/jumin.v7i3.8408

Keywords:

Framingham Risk Score, Asam Urat, Penyakit Jantung Koroner

Abstract

Penyakit jantung koroner merupakan salah satu penyakit kardiovaskular menjadi penyebab utama kematian yang berkaitan erat dengan proses aterosklerosis dan akumulasi faktor risiko metabolik. Penilaian risiko berbasis populasi menjadi penting pada wilayah yang mengalami transisi epidemiologi, seperti Kota Jayapura. Framingham Risk Score (FRS) banyak digunakan untuk memprediksi risiko PJK, namun kinerjanya dapat bervariasi antar populasi sehingga diperlukan eksplorasi biomarker tambahan seperti kadar asam urat. Penelitian ini bertujuan menganalisis risiko PJK pada populasi dewasa di Kota Jayapura menggunakan kombinasi FRS dan kadar asam urat. Metode penelitian ini menggunakan studi observasional analitik dengan desain potong lintang yang melibatkan 38 responden dewasa berusia 30–70 tahun. Risiko PJK dihitung menggunakan FRS dan dikombinasikan dengan pemeriksaan kadar asam urat. Analisis hubungan antar variabel menggunakan uji Chi-square. Hasil penelitian menunjukkan bahwa mayoritas responden berada pada kategori risiko rendah (47,4%), diikuti risiko menengah (31,6%) dan tinggi (21,1%). Tidak terdapat hubungan yang signifikan antara kadar asam urat dengan tingkat risiko PJK (p=0,405). Kesimpulan penelitian ini menunjukkan bahwa kadar asam urat belum dapat digunakan sebagai indikator utama dalam penilaian risiko PJK, namun berpotensi sebagai faktor tambahan dalam stratifikasi risiko kardiovaskular.

Downloads

Download data is not yet available.

References

M. D. Cesare et al., “World Heart Report 2023: Confronting the World’s Number One Killer,” 2023. [Online]. Available: https://world-heart-federation.org/wp-content/uploads/World-Heart-Report-2023.pdf

A. Groenewegen, F. H. Rutten, A. Mosterd, and A. W. Hoes, “Epidemiology of heart failure,” Eur. J. Heart Fail., vol. 22, no. 8, pp. 1342–1356, 2020, doi: 10.1002/ejhf.1858.

W. Frąk, A. Wojtasińska, W. Lisińska, E. Młynarska, B. Franczyk, and J. Rysz, “Pathophysiology of Cardiovascular Diseases: New Insights into Molecular Mechanisms of Atherosclerosis, Arterial Hypertension, and Coronary Artery Disease,” Biomedicines, vol. 10, no. 8, 2022, doi: 10.3390/biomedicines10081938.

D. Glovaci, W. Fan, and N. D. Wong, “Epidemiology of Diabetes Mellitus and Cardiovascular Disease,” Curr. Cardiol. Rep., vol. 21, no. 4, pp. 1–8, 2019, doi: 10.1007/s11886-019-1107-y.

M. A. Khan et al., “Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study,” Cureus, vol. 12, no. 7, 2020, doi: 10.7759/cureus.9349.

B. Kemenkes, “Survei Kesehatan Indonesia (SKI) Dalam Angka,” 2023.

J. P. Duggan, A. S. Peters, G. D. Trachiotis, and J. L. Antevil, “Epidemiology of Coronary Artery Disease,” Surg. Clin. North Am., vol. 102, no. 3, pp. 499–516, 2022, doi: 10.1016/j.suc.2022.01.007.

F. P. Mariachiara Di Cesare, Honor Bixby, Thomas Gaziano, Lisa Hadeed, Chodziwadziwa Kabudula, Diana Vaca McGhie, Jeremiah Mwangi, Borjana Pervan, Pablo Perel, Daniel Piñeiro, Sean Taylor, “World Heart Report 2023,” 2023.

C. Andersson, M. Nayor, C. W. Tsao, D. Levy, and R. S. Vasan, “Framingham Heart Study,” J. Am. Coll. Cardiol., vol. 77, no. 21, pp. 2680–2692, 2021, doi: 10.1016/j.jacc.2021.01.059.

J. A. Damen et al., “Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: A systematic review and meta-analysis,” BMC Med., vol. 17, no. 1, pp. 1–16, 2019, doi: 10.1186/s12916-019-1340-7.

C. Andersson, A. D. Johnson, E. J. Benjamin, D. Levy, and R. S. Vasan, “70-year legacy of the Framingham Heart Study,” Nat. Rev. Cardiol., vol. 16, no. 11, pp. 687–698, 2019, doi: 10.1038/s41569-019-0202-5.

A. Farokhrouz et al., “Racial / Ethnic Differences in Framingham Risk Score in an NHANES Cohort,” vol. 3, no. 3, pp. 17–33, 2024, doi: 10.14302/issn.2474.

S. Das, L. Biswas, T. Mukherjee, and K. Biswas, “Predictive ability of Framingham risk score in Indian population - A retrospective study in a tertiary care hospital in patients with first acute coronary syndrome,” vol. 13, no. 8, pp. 133–139, 2022, doi: 10.3126/ajms.v13i8.45309.

Y. Saito, A. Tanaka, K. Node, and Y. Kobayashi, “Uric acid and cardiovascular disease: A clinical review,” J. Cardiol., vol. 78, no. 1, pp. 51–57, 2021, doi: 10.1016/j.jjcc.2020.12.013.

M. Dong, X. Chen, J. Liu, and C. Li, “Non-conventional lipid parameters predict the risk of rapid kidney function decline in patients with cardiovascular-kidney-metabolic syndrome : The first cohort study evidence from CHARLS,” Exp. Gerontol., vol. 210, no. September, p. 112892, 2025, doi: 10.1016/j.exger.2025.112892.

A. Maloberti et al., “Uric acid in chronic coronary syndromes: Relationship with coronary artery disease severity and left ventricular diastolic parameter,” Nutr. Metab. Cardiovasc. Dis., vol. 31, no. 5, pp. 1501–1508, 2021, doi: 10.1016/j.numecd.2021.01.023.

S. J. Lee, B. K. Oh, and K. C. Sung, “Uric acid and cardiometabolic diseases,” Clin. Hypertens., vol. 26, no. 1, pp. 1–7, 2020, doi: 10.1186/s40885-020-00146-y.

M. E. Gherghina, I. Peride, M. Tiglis, T. P. Neagu, A. Niculae, and I. A. Checherita, “Uric Acid and Oxidative Stress—Relationship with Cardiovascular, Metabolic, and Renal Impairment,” Int. J. Mol. Sci., vol. 23, no. 6, 2022, doi: 10.3390/ijms23063188.

S. Zhang, X. Liu, B. Song, H. Yu, X. Zhang, and Y. Shao, “Impact of serum uric acid levels on the clinical prognosis and severity of coronary artery disease in patients with acute coronary syndrome and hypertension after percutaneous coronary intervention: A prospective cohort study,” BMJ Open, vol. 12, no. 1, 2022, doi: 10.1136/bmjopen-2021-052031.

R. S. Vasan, D. M. Enserro, A. S. Beiser, and V. Xanthakis, “Lifetime Risk of Heart Failure Among Participants in the Framingham Study,” vol. 79, no. 3, 2022.

W. S. Naomi, I. Picauly, and S. M. Toy, “Faktor Risiko Kejadian Penyakit Jantung Koroner,” Media Kesehat. Masy., vol. 3, no. 1, pp. 99–107, 2021, doi: 10.35508/mkm.v3i1.3622.

U. C. Okorafor, C. I. Okorafor, C. Amadi, O. Onyinye, and N. Achime, “Correlation of Serum Uric Acid With Cardiovascular Risk in Nigerian Patients,” Cureus Part Springer Nat., vol. 16, no. 9, 2024, doi: 10.7759/cureus.70285.

A. Wang et al., “Metabolic factors mediate the association between serum uric acid to serum creatinine ratio and cardiovascular disease,” J. Am. Heart Assoc., vol. 10, no. 23, 2021, doi: 10.1161/JAHA.121.023054.

E. Febrianti, A. Asrori, and N. Nurhayati, “Hubungan Antara Peningkatan Kadar Asam Urat Darah Dengan Kejadian Hipertensi Di Rumah Sakit Bhayangkara Palembang Tahun 2018,” J. Anal. Kesehat., vol. 8, no. 1, p. 17, 2019, doi: 10.26630/jak.v8i1.1643.

Y. Kimura, D. Tsukui, and H. Kono, “Uric acid in inflammation and the pathogenesis of atherosclerosis,” Int. J. Mol. Sci., vol. 22, no. 22, 2021, doi: 10.3390/ijms222212394.

K. Li et al., “The potential relationship of coronary artery disease and hyperuricemia: A cardiometabolic risk factor,” Heliyon, vol. 9, no. 5, p. e16097, 2023, doi: 10.1016/j.heliyon.2023.e16097.

W. Yu and J. D. Cheng, “Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective,” Front. Pharmacol., vol. 11, no. November, pp. 1–13, 2020, doi: 10.3389/fphar.2020.582680.